The latest price target for Ligand Pharmaceuticals (NASDAQ:LGND) was reported by RBC Capital on May 8, 2026. The analyst firm set a price target for $262.00 expecting LGND to rise to within 12 months (a possible 2.64% upside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for Ligand Pharmaceuticals (NASDAQ:LGND) was provided by RBC Capital, and Ligand Pharmaceuticals maintained their outperform rating.

There is no last upgrade for Ligand Pharmaceuticals

There is no last downgrade for Ligand Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ligand Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ligand Pharmaceuticals was filed on May 8, 2026 so you should expect the next rating to be made available sometime around May 8, 2027.

While ratings are subjective and will change, the latest Ligand Pharmaceuticals (LGND) rating was a maintained with a price target of $252.00 to $262.00. The current price Ligand Pharmaceuticals (LGND) is trading at is $255.25, which is within the analyst’s predicted range.